Vermillion
Aspira Collaborating With Baylor Genetics on Ovarian Cancer Early Detection Test
Aspira said it will bring its experience in patient sample recruitment and ovarian cancer assay development to the collaboration.
Aspira Eyes $11M in Private Equity Financing
Investors in the company, formerly known as Vermillion, have agreed to purchase $11 million in unregistered common stock at a price of $3.50 per share.
Aspira Labs to Evaluate GenomeSmart Genetic Test Recommendation Platform
The platform matches a patient's medical history and other data with national guidelines to recommended medically actionable genetic tests.
Vermillion Q4 Revenues Up 123 Percent
The company posted an 11 percent year-over-year decline in OVA1 sales but more than doubled its average revenue per test, to $301 from $143 in Q4 2015.
Vermillion, Quest Extend, Amend Ovarian Cancer Test Deal
The firms extended their OVA1 commercialization agreement an additional year while adding procedures for verifying the number of tests performed under the deal.
Feb 14, 2017
Vermillion Aims to Raise $10.7M
Nov 10, 2016
Vermillion Q3 Revenues Up 89 Percent
Aug 19, 2016
May 16, 2016
Vermillion Q1 Revenues Down 47 Percent
Mar 21, 2016
Vermillion Receives FDA 510(k) Clearance for Overa
Jan 22, 2016
Dec 1, 2015
Vermillion Wins Medi-Cal Coverage for OVA1
Nov 20, 2015
Nov 12, 2015
Vermillion Q3 Revenues Up 2 Percent
Oct 30, 2015
Oct 26, 2015